



DiaSorin

# FY 2022 RESULTS

March 27, 2023

# DISCLAIMER

***In General.*** This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the "Presentation". This Presentation has been prepared by DiaSorin S.p.A. ("DiaSorin" or the "Company" and, together with its subsidiary the "Group"). The Presentation is being furnished to you for information purposes only and for use in presentations of the industrial plan of the Group.

***Verbal explanation.*** This Presentation has to be accompanied by a verbal explanation. A simple reading of this Presentation without the appropriate verbal explanation could give rise to a partial or incorrect understanding.

***No offer to purchase or sell securities.*** The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

No distribution of this Presentation. This Presentation is being furnished to you solely for your information and may not be reproduced, in whole or in part, or redistributed to any other individual or legal entity.

***Miscellanea.*** This Presentation has been prepared on a voluntary basis. DiaSorin is therefore not bound to prepare similar presentations in the future, unless where provided by law. Neither the Company nor any member of the Group nor any of its or their respective representatives, directors, employees or agents accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.

Piergiorgio Pedron, the manager responsible for the preparation of the company accounting documents for DiaSorin S.p.A., declares that, pursuant to Article 154-bis, paragraph 2, of the Legislative Decree February 24, 1998, no. 58, to the best of his knowledge, the accounting information included in this Presentation correspond to document results, books and accounting records.

# FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaSorin may make forward-looking statements orally to analysts, investors, representatives of the media and others. In particular, among other statements, certain statements regarding future financial performance, the achievement of certain targeted metrics at any future date or for any future period, trends in results of operations, margins, costs, return on capital, risk management and competition are forward-looking in nature. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance and are, by their nature, subject to inherent risks, uncertainties and assumptions that are difficult to predict because they relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Forward-looking statements do not take into account any additional effects that may arise from impacts on the global market in which DiaSorin operates and, more generally, on the macroeconomic scenario, also following any eventual governmental measures related to the spread of COVID-19 and any potential delay in the vaccination campaign.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the impact of the COVID-19 pandemic, the ability of the Group to create and launch new products successfully; changes in the global financial markets, general economic environment and changes in demand for diagnostic/healthcare/life sciences products, which is subject to cyclicity; changes in local economic and political conditions, changes in trade policy and the imposition of global and regional tariffs or tariffs targeted to the diagnostic/healthcare/life sciences industry, the enactment of tax reforms or other changes in tax laws and regulations; the Group’s ability to offer innovative, attractive products; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims, investigations and lawsuits; material operating expenditures in relation to compliance with health and safety regulations; the intense level of competition in the diagnostic/healthcare/life sciences industry, which may increase due to consolidation; the Group’s ability to fund its defined benefit pension plans; the ability to access funding to execute the its business plans and improve its own businesses, financial condition and results of operations; the Group’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; commercial risk due the fact that the Group operates in a market characterized by the presence of large competitors; risk associated to the maintenance of relationship with customers and strategic partners; risks associated with relationships with employees and suppliers; increases in costs, disruptions of supply or shortages of raw materials; developments in labor and industrial relations and developments in applicable labor laws; exchange rate fluctuations, interest rate changes, credit risk and other market risks; political and civil unrest; earthquakes or other disasters.

Any forward-looking statements contained in this document speak only as of the date of this document and DiaSorin disclaim any obligation to update or revise publicly forward-looking statements. Further information concerning the Group and its business, including factors that could materially affect the Group’s financial results, are included in DiaSorin’s reports and filings with CONSOB and Borsa Italiana.

**No update.** The information and opinions in this document is provided to you as of the dates indicated and DiaSorin does not undertake to update the information contained in this document and/or any opinions expressed relating thereto after its presentation, even in the event that the information becomes materially inaccurate, except as otherwise required by applicable laws.

**Non-IFRS and Other Performance Measures.** This document contains certain items as part of the financial disclosure, which are not defined under IFRS. Accordingly, these items do not have standardized meanings and may not be directly comparable to similarly-titled items adopted by other entities. DiaSorin management has identified a number of “Alternative Performance Indicators” (“APIs”). These APIs (i) are derived from historical results of DiaSorin and are not intended to be indicative of future performance, (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APIs presented herein include EBIT<sup>1</sup>, EBITDA<sup>2</sup>, adjusted EBITDA<sup>3</sup>, Net Financial Position<sup>4</sup> and Free Cash Flow<sup>5</sup>. These measures are not indicative of historical operating results, nor are they meant to be predictive of future results. These measures are used by the management to monitor the underlying performance of the business and operations. Similarly entitled non-IFRS financial measures reported by other companies may not be calculated in an identical manner, consequently the measures reported in this document may not be consistent with similar measures used by other companies. Therefore, investors should not place undue reliance on this data.

1 EBIT is defined as the “Operating Result” net of interests and taxes – 2 EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group’s operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group’s operating result performance. - 3 Adjusted EBITDA is defined as Adjusted EBITDA, excluding extraordinary costs and expenses incurred in the Luminex transaction announced on April 11, 2021 - 4 The Net Financial Position is defined as the algebraic sum (positive balance sheet assets and negative balance sheet liabilities) of cash and cash equivalents and other current financial assets, minus current financial liabilities and non-current financial liabilities.-5 Free Cash Flow is defined as the set of means available to the Company and is equal to cash flows deriving from operating activities net of interest received or paid, and net of investments and divestments of fixed assets.

The background features a dark blue gradient with intricate, glowing geometric patterns in shades of cyan and green. These patterns consist of interconnected lines and dots, resembling a network or a complex crystalline structure. A large, white, rounded rectangular shape is positioned on the left side of the slide, serving as a backdrop for the main title.

# FINANCIAL HIGHLIGHTS

# FINANCIAL HIGHLIGHTS

Data in €/mln

	FY'22	Change	
		@ current	@ CER
<b>Revenues</b>	<b>1,361</b>	<b>+10.0%</b>	<b>+2.4%</b>
Immunodiagnostics ex-COVID	680	+8.4%	+3.3%
Molecular Diagnostics ex-COVID	223	+65.2%	+48.8%
Licensed Technologies	214	+120.6%	+98.1%
COVID	244	-35.5%	-40.1%
<b>Adjusted EBITDA*</b>	<b>514</b>	<b>-5.3%</b>	<b>-11.0%</b>
<i>Adjusted EBITDA Margin</i>	<i>37.8%</i> <i>(38.1% @ CER)</i>		
<b>Adjusted EBIT*</b>	<b>417</b>	<b>-10.3%</b>	
<i>Adjusted EBIT Margin</i>	<i>30.6%</i>		
<b>Adjusted Net Result*</b>	<b>319</b>	<b>-10.7%</b>	
<i>% on revenues</i>	<i>23.4%</i>		
<b>Free Cash Flow</b>	<b>316</b>		
<b>Net Financial Debt</b>	<b>-907</b>		

\* With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the table included in the financial schemes section of this presentation

# KEY FACTS

## PRODUCT & BUSINESS DEVELOPMENT

### IMMUNODIAGNOSTICS

- **FDA 510 (k) clearance** of the **LIAISON® MeMed BV® test**, developed following the licensing agreement signed with MeMed. The test is the first high throughput blood test to **differentiate between viral and bacterial infections**.
- **Validation of 38 tests** on the **LIAISON® XS** platform, bringing the **total amount to 86 tests** and thus making its menu increasingly relevant **for small and medium- sized laboratories**.
- Signing of a **partnership with B·R·A·H·M·S**, part of Thermo Fisher Scientific, for the development and commercialization of the **LIAISON® B·R·A·H·M·S MR-proADM™**, an immunodiagnostic test offering a more precise assessment of disease severity and improving patient management.

# KEY FACTS

## PRODUCT & BUSINESS DEVELOPMENT

### MOLECULAR DIAGNOSTICS

- **New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use Only)** for the detection of mutations associated with the new COVID Omicron variant.
- **CE Marking of ARIES® Flu A/B & RSV+SARS-CoV-2 Assay** for the detection of the 4 most common respiratory viruses and their underlying respiratory infections.
- **FDA 510(k) clearance of Simplexa™ COVID-19 Direct** test for the detection of SARS-CoV-2 from nasal or nasopharyngeal swabs.
- **Launch of Analyte Specific Reagent (ASR)** primer pair to detect the B17R/B18R gene of **monkeypox virus**, responsible for the health emergency declared by the World Health Organization.
- **FDA 510(k) clearance** of the **Simplexa™ Congenital CMV Direct** test for the direct detection of Cytomegalovirus DNA in both saliva swab and urine specimens from babies 21 days old or younger.
- **Extension of collaboration** with **BARDA** (*Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services*) to support the FDA 510(k) clearance of the **LIAISON® NES**.
- **CE marking** of the **xMAP® NxTAG® GPP** Gastrointestinal molecular panel to detect nucleic acids from 16 of the most clinically relevant bacterial, viral, and parasitic pathogens in stool samples on the MAGPIX® platform.
- **FDA 510(K) clearance** of the **Simplexa™ COVID-19 Flu A/B assay** to detect Flu A, Flu B, and SARS-CoV-2 viruses in about an hour

# KEY FACTS


## PRODUCT & BUSINESS DEVELOPMENT

### LICENSED TECHNOLOGIES

- **Sale**, in February 2023, **of the assets related to the Flow Cytometry & Imaging** business unit to Cytek® Biosciences.

# MANAGERIAL OUTLOOK ON FY 2022 REVENUES

Total FY 2022 Group revenues (data in €/mln)



## EVOLUTION OF THE BUSINESS IN 2022

- **Business ex-COVID:** +21% @CER, driven by the inclusion of Luminex in the perimeter of consolidation and the good performance of the Immunodiagnostic and Molecular Diagnostic franchises, also thanks to a very strong flu season.
- **COVID tests contribution:** -40.1% @CER
- **Luminex contribution:** € 386 million.

# REVENUES GROWTH BY GEOGRAPHY AND TECHNOLOGY

## BY GEOGRAPHY (change @ CER)

2022 vs.  
2021

### NORTH AMERICA EX-COVID

<ul style="list-style-type: none"> <li>Positive trend of Immunodiagnostic sales mainly driven by the good performance of the U.S. hospital strategy and specialty tests offering</li> <li>Positive impact from the inclusion of Luminex in the Group perimeter</li> <li>Strong molecular business growth on the back of Luminex contribution and a severe flu season</li> <li>Solid performance of LTG, driven by sales of xMAP® technology, despite issues linked to shortage of certain electronic components causing delays in instrument shipments at the end of 2022</li> </ul>	+43.0%
--	--------

### EUROPE EX-COVID

<ul style="list-style-type: none"> <li>Positive performance of Immunodiagnostics sales (Latent TB, GI panel, ID panel)</li> <li>Positive impact on molecular diagnostic business from the inclusion of Luminex in the Group perimeter and COVID/Flu molecular tests' sales</li> </ul>	+9.8%
---	-------

### REST OF THE WORLD

<ul style="list-style-type: none"> <li>Positive impact from inclusion of Luminex in the Group perimeter</li> <li>Weak performance in China, mainly due to severe COVID local lockdowns and to industrial policies aimed at supporting local operators</li> <li>Lower revenues in certain countries served through distributors (due to delays in certain major shipments and to the situation in Russia and Ukraine)</li> </ul>	+1.4%
---	-------

### COVID

<ul style="list-style-type: none"> <li>Expected negative trend</li> </ul>	-40.1%
---	--------

## BY TECHNOLOGY

2022 vs.  
2021

### IMMUNODIAGNOSTICS EX-COVID

REPORTED	+8.4%
@ CER	+3.3%

### MOLECULAR DIAGNOSTICS EX-COVID

REPORTED	+65.2%
@ CER	+48.8%

### LICENSED TECHNOLOGIES


REPORTED	+120.6%
@ CER	+98.1%

### COVID


REPORTED	-35.5%
@ CER	-40.1%

# FY 2022 REVENUES: MANAGERIAL OUTLOOK

## BY GEOGRAPHY




## BY TECHNOLOGY



# FY 2022 PROFITABILITY PROFILE

(data in €/mln)



- The decrease in Adjusted EBITDA\* margin is mostly due to lower COVID revenues, which had generated significant operating leverage in 2021, only partially offset by the Luminex inclusion in the scope of consolidation.

\* With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation



# FY 2023 COMPANY GUIDANCE

# FY 2023 COMPANY GUIDANCE

## FY 2023 GUIDANCE (@ CER 2022):

- **TOTAL REVENUES:** *approx. -14%*
- **REVENUES AT CONSTANT PERIMETER<sup>1</sup>:** *approx. -11%, of which:*
  - *ex-COVID revenues, net of molecular respiratory business: +4% / + 6%*
  - *Molecular respiratory business revenues: approx. -20%*
  - *COVID revenues: about € 60 million (approx. -75% compared to 2022)*
- **ADJUSTED EBITDA<sup>2</sup> MARGIN:** *approx. 34%*

<sup>1</sup> Excluding the flow cytometry business, sold in February 2023

<sup>2</sup> With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation





# FINANCIAL SCHEMES

# INCOME STATEMENT

(Amounts in million of euros)	FY		Change	
	2021	2022	amount	%
<b>Net Revenues</b>	<b>1,237.7</b>	<b>1,361.1</b>	<b>+123.5</b>	<b>+10.0%</b>
Cost of sales	(412.9)	(460.5)	-47.6	+11.5%
<b>Gross profit</b>	<b>824.8</b>	<b>900.6</b>	<b>+75.8</b>	<b>+9.2%</b>
	66.6%	66.2%	-47 bps	
Sales and marketing expenses	(211.3)	(292.1)	-80.7	+38.2%
Research and development costs	(70.1)	(96.9)	-26.8	+38.3%
General and administrative expenses	(93.3)	(122.7)	-29.4	+31.6%
<b>Total operating expenses</b>	<b>(374.7)</b>	<b>(511.7)</b>	<b>-136.9</b>	<b>+36.5%</b>
	30.3%	37.6%	+731 bps	
Other operating income (expense)	(30.6)	(37.7)	-7.1	+23.3%
<i>non recurring amount</i>	(21.9)	(24.1)	-2.2	+9.9%
<b>EBIT</b>	<b>419.5</b>	<b>351.3</b>	<b>-68.2</b>	<b>-16.3%</b>
	33.9%	25.8%	-809 bps	
Net financial income (expense)	(20.2)	(25.3)	-5.2	+25.6%
<b>Profit before taxes</b>	<b>399.3</b>	<b>325.9</b>	<b>-73.4</b>	<b>-18.4%</b>
Income taxes	(88.6)	(85.8)	+2.8	-3.1%
<b>Net result</b>	<b>310.7</b>	<b>240.1</b>	<b>-70.6</b>	<b>-22.7%</b>
<b>EBITDA<sup>1</sup></b>	<b>515.5</b>	<b>497.3</b>	<b>-18.2</b>	<b>-3.5%</b>
	41.7%	36.5%	-512 bps	

<sup>1</sup> EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

# RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS

<i>(amounts in million of Euro)</i>	Gross Margin	EBITDA	EBIT	Net Profit
<b>IFRS Financial Statements Measures</b>	<b>900.6</b>	<b>497.3</b>	<b>351.3</b>	<b>240.1</b>
<b>% on Revenues</b>	66.2%	36.5%	25.8%	17.6%
<b>Adjustments</b>				
<i>Fair value</i> measurement of the initial Luminex inventory	3.2	3.2	3.2	3.2
“One-off” Costs related to the acquisition, integration and restructuring of Luminex	-	13.7	13.7	13.7
Depreciation of Luminex intangibles identified in the <i>Purchase Price Allocation</i>	-	-	39.8	39.8
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition net of hedging effects	-	-	-	22.5
Flow cytometry net assets remeasurement as required by IFRS	-	-	9.0	9.0
<b>Total adjustments before tax effect</b>	<b>3.2</b>	<b>16.9</b>	<b>65.8</b>	<b>88.3</b>
Fiscal effect on adjustments	-	-	-	(9.7)
<b>Total Adjustments</b>	<b>3.2</b>	<b>16.9</b>	<b>65.8</b>	<b>78.5</b>
<b>Adjusted Measures</b>	<b>903.8</b>	<b>514.2</b>	<b>417.0</b>	<b>318.7</b>

The alternative performance measures listed in the table should be used as an information supplement to the provisions of IFRS, to assist users of the document in better understanding the economic, equity and financial performance of the Group. Such measures are computed purifying the results of the one-off costs relating to the acquisition and integration of Luminex, of the amortization deriving from the Purchase Price Allocation and of the financial charges associated with the financing of the transaction, including the tax impact. It should also be noted that the method of calculating these adjusted indicators could differ from the methods used by other companies.

# BALANCE SHEET

<i>(Amounts in million of euros)</i>	<b>12/31/2021</b>	<b>12/31/2022</b>	<b>Change</b>
Goodwill and intangibles assets	1,943.4	1,995.1	+51.7
Property, plant and equipment	276.2	268.4	-7.7
Other non-current assets	42.6	38.2	-4.4
Net working capital	361.9	434.0	+72.1
Other non-current liabilities	(270.2)	(309.4)	-39.1
<b>Net Invested Capital</b>	<b>2,353.8</b>	<b>2,426.4</b>	<b>+72.5</b>
<b>Net Financial Debt</b>	<b>(985.9)</b>	<b>(906.6)</b>	<b>+79.3</b>
<b>Total shareholders' equity</b>	<b>1,367.9</b>	<b>1,519.8</b>	<b>+151.8</b>

# CASH FLOW STATEMENT

<i>(Amounts in million of euros)</i>	FY	
	2021	2022
<b>Cash and cash equivalents at the beginning of the period</b>	<b>339.9</b>	<b>403.0</b>
Cash provided by operating activities	400.7	389.3
Cash used in investing activities	(110.4)	(232.0)
Cash provided/(used) in financing activities	1,273.7	(318.6)
Acquisitions of companies and business operations	(1,500.8)	-
<b>Net change in cash and cash equivalents before investments in financial assets</b>	<b>63.1</b>	<b>(161.2)</b>
<b>Net change in cash and cash equivalents</b>	<b>63.1</b>	<b>(161.2)</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>403.0</b>	<b>241.8</b>



DiaSorin